A Phase 2 interventional study of AG013736 in Thyroid Neoplasms, sponsored by Pfizer. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-06-26.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 283 studies in Thyroid Neoplasms with a site in United States — 54 open to participants now, 90 under way, 3 of them phase 3. Thyroid Neoplasms · United States.
Among the 283 studies in Thyroid Neoplasms with a site in United States, this one is the 74th largest by enrollment of the 231 interventional ones that give a count, is one of 13 that started in 2004, is one of 99 in phase 2, and was the 15th registered.
785 studies on the registry are indexed under Thyroid Neoplasms; 204 are open to participants now.
Browse Thyroid Neoplasms studies →54 of the 283 studies in Thyroid Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States, Mexico
Ages 18+
Kaiser Permanente · Sites in United States
Ages 21–45
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Thomas Hope · Sites in United States
Ages 12+
Washington University School of Medicine · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 152 Thyroid Neoplasms studies recruiting now, 96 (63%) set no upper age limit and 27 (18%) stop at 75 or younger; 37 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
283 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 70 · Phase 2 120 · Phase 3 10 · Phase 4 5
First in 1977; this study’s year is marked. 13 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is above the median of 54 across 520 interventional studies indexed under Thyroid Neoplasms.
Median enrollment 35 across the 231 interventional studies, 200 across the 47 observational. Of the 180 that completed or were terminated, 93 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
69 of 283 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 5 studies filed under Thyroid Neoplasms — fewer than ten, so there is no comparison to draw.
27 of the studies in Thyroid Neoplasms with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07023731Arvinas Inc.A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation | 2026-11-30 |
| NCT03099356University of Michigan Rogel Cancer CenterCyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer | 2026-12 |
| NCT06220656Dartmouth-Hitchcock Medical CenterTRAIL Study: Feasibility and Pilot | 2026-12 |
| NCT05366881Adela, InccfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease | 2026-12-31 |
| NCT06207188Mayo ClinicIdentification and Differentiation of Thyroid Nodules by Acoustic Imaging and Viscoelastic Parameters | 2026-12-31 |
Add all 27 to your calendar (.ics) → With an account.
Among the 283 studies in Thyroid Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2 study being conducted at multiple centers in the United States. Patients having thyroid cancer that has spread to other parts of the body (i.e., metastatic) are eligible to participate. Patients must have disease that was not controlled by previous treatment with radioactive iodine (131I) or not be good candidates for such treatment. The purpose of the study is to test whether the angiogenesis inhibitor AG-013736 is an effective treatment for metastatic thyroid cancer as shown by the number of patients in the study who experience significant and durable tumor shrinkage.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: AG013736
AG013736, tablets 5 mg BID daily until tumor progression or toxicity
Percentage of Participants With Objective Response (OR)
Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed response are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as the disappearance of all lesions (target and/or non target). PR are those with at least 30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
Time frame: Baseline until the date of first documented progression or discontinuation from the study due to any cause, assessed every 8 weeks up to 206 weeks
Progression-Free Survival (PFS)
Time in days from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the date of first dose of study medication plus 1). Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").
Time frame: Baseline to disease progression or death due to any cause, assessed every 8 weeks up to 206 weeks
Duration of Response (DR)
Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1. DR was calculated for the subgroup of participants with a confirmed objective tumor response.
Time frame: Baseline to disease progression or discontinuation from study due to any cause, assessed every 8 weeks up to 206 weeks
Overall Survival (OS)
Time in days from the start of study treatment to date of death due to any cause. OS was calculated as the death date minus the date of first dose of study medication plus 1. Death was determined from AE data (where outcome was death) or from follow-up contact data (where the participant current status was death). For participants who were alive, overall survival was censored at the last contact.
Time frame: Baseline to death due to any cause or at least 1 year after the initial dose for the last treated participant
Population Pharmacokinetics for Axitinib (AG-013736) Plasma Concentrations
Population pharmacokinetic analysis involved mixed effects modeling using nonlinear mixed effects modeling (NONMEM) software. The intent of this analysis was to establish a basic population pharmacokinetic model for axitinib (AG-013736) and to determine inter-individual and residual variability in population (oral) clearance, and volume of distribution of drug. Relationship of demographic variables (gender, age, body weight, height and ethnicity), concomitant medications and measures of altered hepatic and renal function were examined by fitting measured axitinib (AG-013736) concentrations.
Time frame: Day 1 (pre-dose), Day 29, Day 57 and then every 8 weeks up to 206 weeks
Plasma Concentrations of Soluble Proteins
Plasma concentrations of soluble proteins (vascular endothelial growth factor \[VEGF\], placental growth factor \[PlGF\] and soluble vascular endothelial growth factor receptor-2 \[sVEGFR2\]) may be associated with tumor angiogenesis or tumor physiology and may correlate with efficacy or biological activity. It is presented as ratio to baseline, which is obtained by dividing the plasma soluble protein concentration at each time point by its concentration at baseline.
Time frame: Day 1 (pre-dose) and then every 8 weeks up to 206 weeks
| Milestone | Axitinib |
|---|---|
| Started | 60 |
| Completed | 0 |
| Not completed | 60 |
| Withdrew: Adverse event | 11 |
| Withdrew: Death | 4 |
| Withdrew: Lack of efficacy | 17 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Progressive disease | 2 |
| Withdrew: Clinical progression | 1 |
| Withdrew: Roll-over to another study | 14 |
| Withdrew: Withdrawal by subject | 9 |
Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed response are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as the disappearance of all lesions (target and/or non target). PR are those with at least 30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
| Percentage of participants | Axitinib |
|---|---|
| Percentage of Participants With Objective Response (OR) | 38.3 (26.1 to 51.8) |
Time in days from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the date of first dose of study medication plus 1). Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").
| Days | Axitinib |
|---|---|
| Progression-Free Survival (PFS) | 459 (302 to 610) |
Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1. DR was calculated for the subgroup of participants with a confirmed objective tumor response.
| Days | Axitinib |
|---|---|
| Duration of Response (DR) | 625 (382 to 1391) |
Time in days from the start of study treatment to date of death due to any cause. OS was calculated as the death date minus the date of first dose of study medication plus 1. Death was determined from AE data (where outcome was death) or from follow-up contact data (where the participant current status was death). For participants who were alive, overall survival was censored at the last contact.
| Days | Axitinib |
|---|---|
| Overall Survival (OS) | 1068 (568 to NA) |
Population pharmacokinetic analysis involved mixed effects modeling using nonlinear mixed effects modeling (NONMEM) software. The intent of this analysis was to establish a basic population pharmacokinetic model for axitinib (AG-013736) and to determine inter-individual and residual variability in population (oral) clearance, and volume of distribution of drug. Relationship of demographic variables (gender, age, body weight, height and ethnicity), concomitant medications and measures of altered hepatic and renal function were examined by fitting measured axitinib (AG-013736) concentrations.
No measurements were reported for this outcome.
Plasma concentrations of soluble proteins (vascular endothelial growth factor \[VEGF\], placental growth factor \[PlGF\] and soluble vascular endothelial growth factor receptor-2 \[sVEGFR2\]) may be associated with tumor angiogenesis or tumor physiology and may correlate with efficacy or biological activity. It is presented as ratio to baseline, which is obtained by dividing the plasma soluble protein concentration at each time point by its concentration at baseline.
No measurements were reported for this outcome.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Axitinib | — | 32/60 (53.3%) | 60/60 (100%) |
| Event | Axitinib |
|---|---|
| Dyspnoea NOSRespiratory, thoracic and mediastinal disorders | 6/60 |
| DehydrationMetabolism and nutrition disorders | 4/60 |
| Chest painGeneral disorders | 3/60 |
| Disease progression NOSGeneral disorders | 3/60 |
| DysphagiaGastrointestinal disorders | 2/60 |
| Pneumonia NOSInfections and infestations | 2/60 |
| AnorexiaMetabolism and nutrition disorders | 2/60 |
| Headache NOSNervous system disorders | 2/60 |
| Airway obstruction NOSRespiratory, thoracic and mediastinal disorders | 2/60 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 2/60 |
| Event | Axitinib |
|---|---|
| FatigueGeneral disorders | 42/60 |
| DiarrhoeaGastrointestinal disorders | 40/60 |
| NauseaGastrointestinal disorders | 30/60 |
| Decreased appetiteMetabolism and nutrition disorders | 28/60 |
| HypertensionVascular disorders | 28/60 |
| HeadacheNervous system disorders | 27/60 |
| DyspepsiaGastrointestinal disorders | 24/60 |
| Weight decreasedInvestigations | 24/60 |
| CoughRespiratory, thoracic and mediastinal disorders | 23/60 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 21/60 |
| Age Continuous(years) | Axitinib |
|---|---|
| Mean | 59.3 ± 13.7 |
| Sex: Female, Male(Participants) | Axitinib |
|---|---|
| Female | 25 |
| Male | 35 |
The record gives a start of Sep 2004, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2012, 3 years 2 months after primary completion. A results delay was requested in Mar 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Axitinib